Streetbeat News

Stock Prices

ACN

Over the last quarter, 17 analysts have provided ratings for Accenture (NYSE:ACN), with 5 being bullish, 4 somewhat bullish, and 8 indifferent. The average 12-month price target for Accenture is $337.41, a 6.04% increase from the previous average of $318.20.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

LOW

In the last quarter, 25 analysts have provided ratings for Lowe's Companies (NYSE:LOW), with 8 being bullish, 7 somewhat bullish, and 10 indifferent. The company has an average 12-month price target of $249.6, which has increased by 5.34% over the past month.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

INZY

Analysts have provided bullish ratings for Inozyme Pharma (NASDAQ:INZY) with an average price target of $18.6, implying an upside from the current price of $4.85. This represents a 2.11% decrease from the previous average price target of $19.00.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

MPC

Marathon Petroleum (NYSE:MPC) has received various analyst ratings in the last quarter, with 2 bullish, 5 somewhat bullish, and 4 indifferent. The company's average price target has increased by 7.59% from the previous average price target of $138.91 to $149.45.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

BJ

Over the past 3 months, 6 analysts have published their opinion on BJ's Wholesale Club (NYSE:BJ) stock. The analysts have an average price target of $75.33 versus the current price of BJ's Wholesale Club at $66.45, implying an upside. This current average represents a 4.44% decrease from the previous average price target of $78.83.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

PGY

Pagaya Techs (NASDAQ:PGY) has received 7 analyst ratings in the last quarter, with 4 being bullish, 2 somewhat bullish, and 1 indifferent. The average price target is $4.46, indicating a potential upside from the current price of $2.2472. This average has increased by 105.53% from the previous average price target of $2.17.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

ARQQ

BIOC

GROM

KR

LTRX

RENT

SWBI

U.S. stocks traded mostly higher with the Nasdaq Composite edging higher. Energy shares jumped by 1.4% while real estate shares fell by 0.7%. The Kroger Co. reported better-than-expected quarterly earnings and reached an opioid settlement agreement. Biocept, Inc., Smith & Wesson Brands, Inc., and Lantronix, Inc. saw their shares rise after positive news. Grom Social Enterprises, Inc., Rent the Runway, Inc., and Arqit Quantum Inc. saw their shares drop after negative news.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 6:57 pm

F

GM

STLA

Stellantis N.V. (NYSE:STLA) has presented its first economic proposal to the United Auto Workers union (UAW), which includes wage increases, inflation protection payments, and an accelerated progression timeline for employees. The current contracts between UAW and Stellantis, General Motors Company (NYSE:GM), and Ford Motor Company (NYSE:F) expire on Sept. 14.

Portfolio Pulse from Erica Kollmann

September 08, 2023 | 6:55 pm

LNW

SCPL

Truist Securities analyst Barry Jonas has reiterated a Buy rating on Light & Wonder, Inc. (NASDAQ:LNW), raising the price target to $86 from $78. This follows a robust Q2 beat and the expected acquisition of SciPlay Corporation (NASDAQ:SCPL) in Q4. Despite industry headwinds, SciPlay continues to see growth. LNW's management also reiterated its $1.4 billion 2025 AEBITDA target, citing expansion into adjacent markets and attracting top game design talent as key contributors.

Portfolio Pulse from Nabaparna Bhattacharya

September 08, 2023 | 6:54 pm

ZVSA

HC Wainwright initiated coverage on ZyVersa Therapeutics Inc (NASDAQ:ZVSA) with a Buy Rating and a price target of $2.50. Despite the stock's steady decline since its IPO, the analyst believes ZyVersa has the potential to build significant stockholder value. The company's initial VAR 200 data in diabetic kidney disease patients in 2Q24 is eagerly anticipated and expected to validate the asset and potentially improve both investor sentiment and ZVSA shares.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 6:52 pm